Compare TEI & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TEI | PLYX |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.9M | 262.3M |
| IPO Year | N/A | N/A |
| Metric | TEI | PLYX |
|---|---|---|
| Price | $5.89 | $7.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 234.8K | ★ 1.9M |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | ★ 10.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.78 | $2.20 |
| 52 Week High | $7.00 | $8.15 |
| Indicator | TEI | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 24.12 | 65.14 |
| Support Level | $5.90 | $2.37 |
| Resistance Level | $6.18 | N/A |
| Average True Range (ATR) | 0.12 | 1.43 |
| MACD | -0.03 | 0.26 |
| Stochastic Oscillator | 24.28 | 72.39 |
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small molecule drug candidates designed to address core pathological mechanisms common to LSDs.